News summary
[Baicheng Pharmaceutical: Subsidiary received BIOS2207 drug clinical trial approval notice] Securities Times e Company NewsyesjilicomBaicheng Pharmaceutical (301096) announced on the evening of May 12 that its wholly-owned subsidiary Zhejiang Thermo Pharmaceutical Co., Ltd. recently received a clinical trial approval notice from the State Food and Drug Administration.yesjilicom...
Newsletter text
[Baicheng Pharmaceutical: The subsidiary received the approval notice for clinical trial of BIOS2207] Securities Times e Company News, Baicheng Pharmaceutical (301096) announced on the evening of May 12 that its wholly-owned subsidiary Zhejiang Thermo Pharmaceutical Co., Ltd. recently received The National Drug Administration's clinical trial approval notice, and the company's independently developed drug BIOS2207 will conduct clinical trials. BIOS2207 is indicated for the treatment of adults and children 4 years of age and older with partial seizures, with or without secondary generalized seizures.